GGrantIndex
← Leaderboards

Roy H Perlis

Massachusetts General Hospital

Google Scholar ↗PubMed ↗ORCID ↗
$23,588,460
Attributed
$35,853,721
Total exposure
16
Grants
13
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $9.7M · FY2005–25
$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$35,853,721 · 16

By mechanism

R01$18,018,359 · 9
UF1$7,013,600 · 1
RF1$4,454,697 · 2
U01$4,252,200 · 1
K23$845,379 · 1
R21$673,731 · 1

Top collaborators

Most similar at Massachusetts General Hospital

Same institution · by research overlap

Others in their field

Top investigators on “Investigation”

Research focus

InvestigationPhenotypeCohortResearch PersonnelMajor Depressive DisorderAntidepressive AgentsPharmaceutical PreparationsMental DisordersResourcesElectronic Health RecordMental DepressionBiobankResponseHealth SystemBaseBiologyCodeVariantEffective TherapyTreatment ResponseFutureLinkHospitalsPublic Health

Grant awards (48)

Scalable Phenotyping to Assay Risk in Childhood after eXposures in Pregnancy: SPARC-XP$7,013,600
UF1 · FY2025 · MH
JASPer-MH: Jointly Assessed Scalable Phenotypes for Mental Health$2,109,289
U01 · FY2025 · MH · contact PI
Characterization of schizophrenia liability genes in models of human microglial synaptic pruning$592,223
R01 · FY2025 · MH
JASPer-MH: Jointly Assessed Scalable Phenotypes for Mental Health$2,142,911
U01 · FY2024 · MH · contact PI
Data-driven subtyping in major depressive disorder$811,567
R01 · FY2024 · MH · contact PI
Characterization of schizophrenia liability genes in models of human microglial synaptic pruning$592,223
R01 · FY2024 · MH
Data-driven subtyping in major depressive disorder$730,411
R01 · FY2023 · MH · contact PI
Patient-derived Models of Synaptic Pruning in Schizophrenia$610,865
R01 · FY2023 · MH · contact PI
Characterization of schizophrenia liability genes in models of human microglial synaptic pruning$608,973
R01 · FY2023 · MH
Cellular models of fetal neurodevelopment in maternal SARS-CoV-2 infection$2,560,905
RF1 · FY2022 · MH
Depression, Isolation, and Social Connectivity Online (DISCO)$1,893,792
RF1 · FY2022 · MH · contact PI
Data-driven subtyping in major depressive disorder$772,025
R01 · FY2022 · MH · contact PI
Patient-derived Models of Synaptic Pruning in Schizophrenia$610,865
R01 · FY2022 · MH · contact PI
1/2 Leveraging electronic health records for pharmacogenomics of psychiatric disorders$421,250
R01 · FY2022 · MH · contact PI
Data-driven subtyping in major depressive disorder$832,192
R01 · FY2021 · MH · contact PI
Patient-derived Models of Synaptic Pruning in Schizophrenia$610,865
R01 · FY2021 · MH · contact PI
1/2 Leveraging electronic health records for pharmacogenomics of psychiatric disorders$421,250
R01 · FY2021 · MH · contact PI
Patient-derived Models of Synaptic Pruning in Schizophrenia$643,013
R01 · FY2020 · MH · contact PI
1/2 Leveraging electronic health records for pharmacogenomics of psychiatric disorders$421,250
R01 · FY2020 · MH · contact PI
Patient-derived Models of Synaptic Pruning in Schizophrenia$643,013
R01 · FY2019 · MH · contact PI
1/2 Leveraging electronic health records for pharmacogenomics of psychiatric disorders$421,250
R01 · FY2019 · MH · contact PI
Patient-Derived Cellular Models of Putative Antidepressants$406,970
R01 · FY2019 · AT · contact PI
Machine learning for data-driven subtyping of major depression$595,755
R56 · FY2018 · MH · contact PI
Genetics of Cardiotoxic Drug Response to Psychiatric Therapy$552,229
R01 · FY2018 · HL · contact PI
Patient-Derived Cellular Models of Putative Antidepressants$406,970
R01 · FY2018 · AT · contact PI
Natural language processing for characterizing psychopathology$376,490
R01 · FY2018 · MH · contact PI
Genetics of Cardiotoxic Drug Response to Psychiatric Therapy$714,263
R01 · FY2017 · HL · contact PI
Patient-Derived Cellular Models of Putative Antidepressants$406,970
R01 · FY2017 · AT · contact PI
Natural language processing for characterizing psychopathology$377,260
R01 · FY2017 · MH · contact PI
Genetics of Cardiotoxic Drug Response to Psychiatric Therapy$714,263
R01 · FY2016 · HL · contact PI
Natural language processing for characterizing psychopathology$413,500
R01 · FY2016 · MH · contact PI
Patient-Derived Cellular Models of Putative Antidepressants$406,970
R01 · FY2016 · AT · contact PI
Genetics of Cardiotoxic Drug Response to Psychiatric Therapy$714,263
R01 · FY2015 · HL · contact PI
Patient-Derived Cellular Models of Putative Antidepressants$406,970
R01 · FY2015 · AT · contact PI
In utero antidepressant exposures and risk for autism$348,000
R01 · FY2015 · MH · contact PI
In utero antidepressant exposures and risk for autism$348,000
R01 · FY2014 · MH · contact PI
In utero antidepressant exposures and risk for autism$343,560
R01 · FY2013 · MH · contact PI
In vitro and in vivo study of simvastatin plus lithium in bipolar depression$214,664
R21 · FY2013 · MH · contact PI
In vitro and in vivo study of simvastatin plus lithium in bipolar depression$191,268
R21 · FY2013 · MH · contact PI
In vitro and in vivo study of simvastatin plus lithium in bipolar depression$267,799
R21 · FY2012 · MH · contact PI
Building a Risk Stratification Model for Treatment Resistance in Major Depressive$437,170
R01 · FY2011 · MH · contact PI
Building a Risk Stratification Model for Treatment Resistance in Major Depressive$441,586
R01 · FY2010 · MH · contact PI
Building a Risk Stratification Model for Treatment Resistance in Major Depressive$459,690
R01 · FY2009 · MH · contact PI
Pramipexole in Treatment-Resistant Depression$176,428
K23 · FY2007 · MH · contact PI
Pramipexole in Treatment-Resistant Depression$172,258
K23 · FY2006 · MH · contact PI
Pramipexole in Treatment-Resistant Depression$168,765
K23 · FY2005 · MH
Pramipexole in Treatment-Resistant Depression$165,818
K23 · FY2004 · MH
Pramipexole in Treatment-Resistant Depression$162,110
K23 · FY2003 · MH